FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra (FAME)
Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra
Sponsor: Biogen
A PHASE4 clinical study on Multiple Sclerosis, this trial is completed. The trial is conducted by Biogen and has accumulated 7 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Sep 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Jun 2018 — Sep 2018 [monthly]
Completed PHASE4
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Jun 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Biogen
- Region of Southern Denmark
- University of Southern Denmark
For direct contact, visit the study record on ClinicalTrials.gov .